The purpose of this study is to determine whether mirtazapine is effective in the treatment of sleep disorders in Alzheimers disease.
Mirtazapine has been used for depressed elderly with sleep disorders with good tolerability and efficacy. The study hypothesis is that mirtazapine could also be used in demented with sleep disorders. Sleep disorders (SD) affects 35 to 50 percent of patients with Alzheimer Disease (AD). These disorders often make caring for patients at home very difficult and It's also associated with higher risk of institutionalization and increases health care costs. Treatment of SD in people with dementia may benefit both patients and their caregivers. However, little is known about the efficacy of pharmacological treatments for treating sleep disturbances in AD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
30
Mirtazapine 15 mg, at night, once a day for 14 days
Brasilia University
Brasília, Federal District, Brazil
RECRUITINGChange From Baseline in Nighttime Total Sleep Time
Mean of Nighttime Total Sleep Time (in minutes) during the 12-h nocturnal epoch 8:00 PM - 08:00 AM after 2 weeks under treatment
Time frame: Baseline, 14 days follow-up
Change From Baseline in Nighttime Number Of Awakenings
Change in scores from baseline to intervention week was analyzed using an analysis of covariance (ANCOVA) with the change score as the dependent variable and the treatment condition and baseline score as independent variables.
Time frame: Baseline, 14 days follow-up
Change From Baseline in Nighttime Wake After Sleep Onset
Nighttime Wake After Sleep Onset (in minutes) after sleep onset until the final awakening during the 12-h nocturnal epoch 8:00 PM - 08:00 AM. After 2 weeks under treatment.
Time frame: Baseline, 14 days follow-up
Change From Baseline in in Daytime Total Sleep Time
Time frame: Baseline, 14 days follow-up
Change From Baseline in Number of Daytime Naps
Time frame: Baseline, 14 days follow-up]
Change in Cognitive Function (as Measured by the Mini-Mental State Examination)
Time frame: Baseline, 14 days follow-up]
Change in Activities of Daily Living (The Index of ADL - Katz)
Time frame: Baseline, 14 days follow-up]
Change of Baseline in Behavioral Variables (BAHAVE-AD Scale)
Time frame: Baseline, 14 days follow-up]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change From Baseline in Cognitive Function (Digit Symbol Substitution Test)
Time frame: Baseline, 14 days follow-up]